AI Article Synopsis

  • Current treatments for neurodegenerative diseases mainly relieve symptoms but do not slow disease progression, highlighting the need for effective therapies.
  • The study investigates the compound FMU200, which inhibits JNK3, for its neuroprotective, anti-inflammatory, and antioxidant properties using cell lines SH-SY5Y and RAW264.7.
  • Results indicate that FMU200 significantly reduces cell damage from neurotoxins, decreases apoptosis, lowers reactive oxygen species, restores mitochondrial function, and diminishes inflammatory responses, suggesting its potential as a treatment option for neurodegenerative disorders.

Article Abstract

Current treatments for neurodegenerative diseases (ND) are symptomatic and do not affect disease progression. Slowing this progression remains a crucial unmet need for patients and their families. c-Jun N-terminal kinase 3 (JNK3) are related to several ND hallmarks including apoptosis, oxidative stress, excitotoxicity, mitochondrial dysfunction, and neuroinflammation. JNK inhibitors can play an important role in addressing neuroprotection. This research aims to evaluate the neuroprotective, anti-inflammatory, and antioxidant effects of a synthetic compound (FMU200) with known JNK3 inhibitory activity in SH-SY5Y and RAW264.7 cell lines. SH-SY5Y cells were pretreated with FMU200 and cell damage was induced by 6-hydroxydopamine (6-OHDA) or hydrogen peroxide (HO). Cell viability and neuroprotective effect were assessed with an MTT assay. Flow cytometric analysis was performed to evaluate cell apoptosis. The HO-induced reactive oxygen species (ROS) generation and mitochondrial membrane potential (ΔΨm) were evaluated by DCFDA and JC-1 assays, respectively. The anti-inflammatory effect was determined in LPS-induced RAW264.7 cells by ELISA assay. In undifferentiated SH-SY5Y cells, FMU200 decreased neurotoxicity induced by 6-OHDA in approximately 20%. In RA-differentiated cells, FMU200 diminished cell death in approximately 40% and 90% after 24 and 48 h treatment, respectively. FMU200 reduced both early and late apoptotic cells, decreased ROS levels, restored mitochondrial membrane potential, and downregulated JNK phosphorylation after HO exposure. In LPS-stimulated RAW264.7 cells, FMU200 reduced TNF-α levels after a 3 h treatment. FMU200 protects neuroblastoma SH-SY5Y cells against 6-OHDA- and HO-induced apoptosis, which may result from suppressing the JNK pathways. Our findings show that FMU200 can be a useful candidate for the treatment of neurodegenerative disorders.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037381PMC
http://dx.doi.org/10.3390/ijms22073701DOI Listing

Publication Analysis

Top Keywords

sh-sy5y cells
16
mitochondrial membrane
12
membrane potential
12
cells fmu200
12
fmu200
9
oxidative stress
8
cells
8
raw2647 cells
8
treatment fmu200
8
fmu200 reduced
8

Similar Publications

Background: The nuclear clearance and cytoplasmic aggregation of splicing repressor TAR DNA/RNA-binding protein-43 (TDP-43) occur in approximately 50% of Alzheimer's disease (AD) cases and about 45% of frontotemporal dementia (FTD). However, it is not clear how early such mechanism occurs in AD and FTD as there is no method of detecting TDP-43 dysregulation in living individuals. Since the loss of nuclear TDP-43 leads to cryptic exon inclusion, we propose that cryptic exon-encoded peptides may be detected in patient biofluids as biomarkers of TDP-43 loss of function.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

All India Institute of Medical Sciences, New Delhi, India.

Background: Recent research on Alzheimer's disease (AD) has highlighted that the oxidative damage is the earliest event of disease. These oxidative modifications are closely associated with inflammatory molecules. It is necessary to explore these two pathways with AD pathophysiology and targeted for therapeutic intervention.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

All India Institute of Medical Sciences, AIIMS, New Delhi, Delhi, India.

Background: Alzheimer's disease (AD) is a progressive brain disorder which leads to gradual decline in memory, thinking, behaviour and social skills. The current scenario for drug development is based on neuro-inflammation and oxidative stress. Amyloid-β (Aβ) deposition, a major hallmark of the disease activates microglia leading to neuro-inflammation and neuro-degeneration induced by activation of COX-2 via NFkB p50 in glioblastoma cells.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

IMDEA Nanociencia, Madrid, Spain.

Background: About half of the patients suffering from Alzheimer's disease (AD) display sleeping disorders. Disruptions in the central circadian clock (CC), located in the brain, accelerate AD pathogenesis, making the CC a promising target. In preclinical trials, this strategy have shown efficacy but clinical results are inconsistent.

View Article and Find Full Text PDF

Background: Recent work suggests that amyloid precursor protein (APP) may be involved in regulating mitochondrial quality control mechanisms. Impaired mitophagy, leading to the accumulation of damaged mitochondria are features of Alzheimer's disease (AD). Conversely, enhancing mitophagy may reduce AD neuropathological change and improve cognitive function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!